Maze Therapeutics (MAZE) vs Novavax (NVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Novavax (NVAX) has outperformed Maze Therapeutics (MAZE) over the past year, gaining 21.7% versus a loss of 5.8%. Novavax is the larger company by market cap ($1.80 billion vs $1.40 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAZE | NVAX |
|---|---|---|
| Share price | $25.24 | $10.91 |
| Market cap | $1.40B | $1.80B |
| 1-day change | -3.85% | -2.80% |
| YTD return | -36.64% | +66.96% |
| 1-year return | -5.78% | +21.69% |
| 5-year return | — | -93.07% |
| EPS (TTM) | $-2.48 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $53.65 | $13.39 |
| 52-week low | $21.95 | $6.20 |
| Distance from 52-week high | -52.95% | -18.55% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +143.66% | +28.37% |
| Average volume | 560.26K | 5.16M |
| Shares outstanding | 55.55M | 164.95M |
| Employees | 141 | 749 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVAX has outperformed MAZE by 27.5 percentage points over the past year.
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
MAZE vs NVAX FAQ
Which is bigger, Maze Therapeutics or Novavax?
Novavax (NVAX) is larger, with a market capitalization of $1.80B compared with $1.40B for Maze Therapeutics (MAZE).
Which stock has performed better over the past year, MAZE or NVAX?
NVAX returned +21.69% over the past 12 months, compared with -5.78% for MAZE (price return, excluding dividends). Past performance does not predict future results.
Are Maze Therapeutics and Novavax in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.